A Phase I, Open-Label, Multicenter, 3-Period, Fixed-Sequence Study To Investigate The Effect Of Vemurafenib On The Pharmacokinetics Of A Single Dose Of Digoxin In Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
Phase of Trial: Phase I
Latest Information Update: 25 Sep 2015
At a glance
- Drugs Digoxin (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Pharmacokinetics
- Sponsors Roche
- 04 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 08 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 25 Mar 2014 Planned End Date changed from 1 Jan 2015 to 1 Jul 2014 as reported by ClinicalTrials.gov.